The FDA has approved Akten (lidocaine ophthalmic gel 3.5%, from Akorn), a topical, preservative-free anesthetic for use in ocular procedures, including intravitreal injection and cataract, refractive and Lasik surgery. This approval was based on results from a randomized, placebo-controlled trial of 209 patients who met the primary endpoint in all three dosing arms of the study.

Akten is expected to be available in October 2008.

For more information call (800) 932-5676 or visit www.akorn.com.